Management of immunosuppressive drugs in HIV-positive solid organ transplant recipients

Shao Kun; Wang Xianghui; Zhou Peijun

doi:10.3969/j.issn.1674-7445.2024009

Article Contents

Article Navigation > ORGAN TRANSPLANTATION > 2024 >

Shao Kun, Wang Xianghui, Zhou Peijun. Management of immunosuppressive drugs in HIV-positive solid organ transplant recipients[J]. ORGAN TRANSPLANTATION. doi: 10.3969/j.issn.1674-7445.2024009

Citation:

Shao Kun, Wang Xianghui, Zhou Peijun. Management of immunosuppressive drugs in HIV-positive solid organ transplant recipients[J]. ORGAN TRANSPLANTATION. doi: 10.3969/j.issn.1674-7445.2024009

Citation:

Shao Kun, Wang Xianghui, Zhou Peijun. Management of immunosuppressive drugs in HIV-positive solid organ transplant recipients[J]. ORGAN TRANSPLANTATION. doi: 10.3969/j.issn.1674-7445.2024009

PDF( 558 KB)

Management of immunosuppressive drugs in HIV-positive solid organ transplant recipients

doi: 10.3969/j.issn.1674-7445.2024009

Shao Kun^{1, 2
,
,},
Wang Xianghui^{1, 2},
Zhou Peijun^{1, 2}

1.
Depatrment of Urology, Shanghai Jiao Tong University School of Medicine Affiliated Ruijin Hospital, Shanghai 200025, China

More Information

Corresponding author: Shao Kun, Email: shaokunrj@163.com
Received Date: 2024-01-26
Available Online: 2024-04-29

Abstract

Abstract

The application of combination antiretroviral therapy (cART) has significantly prolonged the life expectancy of patients infected with human immunodeficiency virus (HIV). However, viral infection and adverse reactions of cART drugs make patients more prone to organ failure. Solid organ transplantation (SOT) has become a standard treatment for HIV-infected patients with end-stage organ failure. Nevertheless, among HIV-positive SOT recipients, multiple problems remain to be resolved, such as increased incidence of graft rejection, increased infection risk, drug toxicity and drug interaction between cART therapy and immunosuppressive drugs, etc. It is extremely challenging to deliver appropriate management for HIV-positive SOT recipients. Therefore, the application of immune induction therapy, calcineurin inhibitors, mammalian target of rapamycin (mTOR) inhibitors and other immunosuppressive drugs in HIV-positive SOT recipients was reviewed, aiming to provide reference for subsequent related studies.
- Human immunodeficiency virus,
- Solid organ transplantation,
- Combination antiretroviral therapy,
- Immune induction,
- Calcineurin inhibitor,
- Mammalian target of rapamycin inhibitor,
- Mycophenolic acid,
- Glucocorticoid

FullText(HTML)

References(39)

References

[1]	The path that ends AIDS: UNAIDS Global AIDS Update 2023[EB/OL]. [2024-01-07].https://www.unaids.org/sites/default/files/media_asset/2023-unaids-global-aids-update_en.pdf.
[2]	芦佳骏, 费发珠, 任宾. HIV感染者非酒精性脂肪性肝病的临床研究进展[J]. 临床肝胆病杂志, 2023, 39(6): 1446-1453. DOI: 10.3969/j.issn.1001-5256.2023.06.030. LU JJ, FEI FZ, REN B. Research advances in nonalcoholic fatty liver disease in individuals with HIV infection[J]. J Clin Hepatol, 2023, 39(6): 1446-1453. DOI: 10.3969/j.issn.1001-5256.2023.06.030.
[3]	邵莉, 陈继军, 包凯, 等. 基于贝叶斯Cox风险比例回归的兰州市HIV感染者/AIDS患者死亡影响因素分析[J]. 中山大学学报(医学科学版), 2023, 44(2): 224-231. DOI: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2023.0206. SHAO L, CHEN JJ, BAO K, et al. Influencing factors of HIV/ AIDS death based on Bayesian Cox proportional hazard regression model[J]. J Sun Yat-sen Univ (Med Sci), 2023, 44(2): 224-231. DOI: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2023.0206.
[4]	POURNAMDARI AB, HSUE PY, PARIKH RV. HIV-associated cardiovascular disease: beyond the macrovascular[J]. J Am Heart Assoc, 2023, 12(22): e031876. DOI: 10.1161/JAHA.123.031876.
[5]	CERVANTES CE, ATTA MG. Updates on HIV and kidney disease[J]. Curr HIV/AIDS Rep, 2023, 20(2): 100-110. DOI: 10.1007/s11904-023-00645-1.
[6]	NAVARRO J. HIV and liver disease[J]. AIDS Rev, 2022, 25(2): 87-96. DOI: 10.24875/AIDSRev.M22000052.
[7]	STOCK PG, BARIN B, MURPHY B, et al. Outcomes of kidney transplantation in HIV-infected recipients[J]. N Engl J Med, 2010, 363(21): 2004-2014. DOI: 10.1056/NEJMoa1001197.
[8]	COFFIN CS, STOCK PG, DOVE LM, et al. Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients[J]. Am J Transplant, 2010, 10(5): 1268-1275. DOI: 10.1111/j.1600-6143.2010.03070.x.
[9]	KUMAR RN, STOSOR V. Advances in liver transplantation for persons with human immunodeficiency infection[J]. Curr Infect Dis Rep, 2022, 24(3): 39-50. DOI: 10.1007/s11908-022-00776-3.
[10]	郑鑫, 胡小鹏, 薛文瑞, 等. HIV阳性患者接受亲属活体供肾移植一例及文献复习[J]. 中华器官移植杂志, 2019, 40(2): 88-91. DOI: 10.3760/cma.j.issn.0254-1785.2019.02.006. ZHENG X, HU XP, XUE WR, et al. HIV-positive patient receiving living related renal transplantation: a report of one case and literature review[J]. Chin J Organ Transplant, 2019, 40(2): 88-91. DOI: 10.3760/cma.j.issn.0254-1785.2019.02.006.
[11]	冯文霞, 董常峰, 冯程, 等. 超声在HIV感染合并乙型病毒性肝炎肝硬化患者肝移植中的应用[J/CD]. 新发传染病电子杂志, 2021, 6(4): 294-297. DOI: 10.19871/j.cnki.xfcrbzz.2021.04.006. FENG WX, DONG CF, FENG C, et al. Ultrasound application in liver transplantation for HIV-infected patients with concomitant hepatitis B virus-related liver cirrhosis[J/CD]. Electr J Emerg Infect Dis, 2021, 6(4): 294-297. DOI: 10.19871/j.cnki.xfcrbzz.2021.04.006
[12]	赖宇婷, 赵宁波, 董常峰, 等. 超声对HIV感染患者肾移植术后的诊治分析[J]. 罕少疾病杂志, 2023, 30(6): 38-40. DOI: 10.3969/j.issn.1009-3257.2023.06.017. LAI YT, ZHAO NB, DONG CF, et al. Analysis of diagnosis and treatment for HIV-infected patients after kidney transplantation with ultrasound[J]. J Rare Uncommon Dis, 2023, 30(6): 38-40. DOI: 10.3969/j.issn.1009-3257.2023.06.017.
[13]	Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS). Organ procurement and transplantation: implementation of the HIV Organ Policy Equity act. final rule[J]. Fed Regist, 2015, 80(89): 26464-26467.
[14]	LAGOUTTE-RENOSI J, FLAMMANG M, DUCLOUX D, et al. Bictegravir/emtricitabine/tenofovir alafenamide combination in the management of kidney transplant patients with HIV receiving immunosuppressants[J]. J Chemother, 2022, 34(3): 199-202. DOI: 10.1080/1120009X.2021.1940436.
[15]	ALMANGOUR TA, SKERSICK PT, CORBETT A, et al. Heart transplantation and human immunodeficiency virus-navigating drug-drug interactions: a case report[J]. AIDS Res Ther, 2023, 20(1): 55. DOI: 10.1186/s12981-023-00551-x.
[16]	MCCAIN JD, CHASCSA DM. Special considerations in the management of HIV and viral hepatitis coinfections in liver transplantation[J]. Hepat Med, 2022, 14: 27-36. DOI: 10.2147/HMER.S282662.
[17]	CARTER JT, MELCHER ML, CARLSON LL, et al. Thymoglobulin-associated CD4⁺ T-cell depletion and infection risk in HIV-infected renal transplant recipients[J]. Am J Transplant, 2006, 6(4): 753-760. DOI: 10.1111/j.1600-6143.2006.01238.x.
[18]	FERNÁNDEZ-RUIZ M, LÓPEZ-MEDRANO F, ALLENDE LM, et al. Kinetics of peripheral blood lymphocyte subpopulations predicts the occurrence of opportunistic infection after kidney transplantation[J]. Transpl Int, 2014, 27(7): 674-685. DOI: 10.1111/tri.12321.
[19]	ROLAND ME, BARIN B, HUPRIKAR S, et al. Survival in HIV-positive transplant recipients compared with transplant candidates and with HIV-negative controls[J]. AIDS, 2016, 30(3): 435-444. DOI: 10.1097/QAD.0000000000000934.
[20]	KUCIRKA LM, DURAND CM, BAE S, et al. Induction Immunosuppression and clinical outcomes in kidney transplant recipients infected with human immunodeficiency virus[J]. Am J Transplant, 2016, 16(8): 2368-2376. DOI: 10.1111/ajt.13840.
[21]	LYNCH EN, RUSSO FP. Liver transplantation in people living with HIV: still an experimental procedure or standard of care?[J]. Life (Basel), 2023, 13(10): 1975. DOI: 10.3390/life13101975.
[22]	KOVAL CE, FARR M, KRISL J, et al. Heart or lung transplant outcomes in HIV-infected recipients[J]. J Heart Lung Transplant, 2019, 38(12): 1296-1305. DOI: 10.1016/j.healun.2019.09.011.
[23]	DOBERNE JW, JAWITZ OK, RAMAN V, et al. Heart transplantation survival outcomes of HIV positive and negative recipients[J]. Ann Thorac Surg, 2021, 111(5): 1465-1471. DOI: 10.1016/j.athoracsur.2020.06.120.
[24]	LAM C, LANDRY S, MOUSSA G, et al. Pharmacotherapeutic interventions in people living with HIV undergoing solid organ transplantation: a scoping review[J]. Transplant Direct, 2023, 9(2): e1441. DOI: 10.1097/TXD.0000000000001441.
[25]	BLUMBERG EA, ROGERS CC, American Society of Transplantation Infectious Diseases Community of Practice. Solid organ transplantation in the HIV-infected patient: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice[J]. Clin Transplant, 2019, 33(9): e13499. DOI: 10.1111/ctr.13499.
[26]	MAMATIS JE, PELLIZZARI-DELANO IE, GALLARDO-FLORES CE, et al. Emerging roles of cyclophilin A in regulating viral cloaking[J]. Front Microbiol, 2022, 13: 828078. DOI: 10.3389/fmicb.2022.828078.
[27]	HAN J, LEE MK, JANG Y, et al. Repurposing of cyclophilin A inhibitors as broad-spectrum antiviral agents[J]. Drug Discov Today, 2022, 27(7): 1895-1912. DOI: 10.1016/j.drudis.2022.05.016.
[28]	GATHOGO E, HARBER M, BHAGANI S, et al. Impact of tacrolimus compared with cyclosporin on the incidence of acute allograft rejection in human immunodeficiency virus-positive kidney transplant recipients[J]. Transplantation, 2016, 100(4): 871-878. DOI: 10.1097/TP.0000000000000879.
[29]	VAN MAARSEVEEN EM, ROGERS CC, TROFE-CLARK J, et al. Drug-drug interactions between antiretroviral and immunosuppressive agents in HIV-infected patients after solid organ transplantation: a review[J]. AIDS Patient Care STDS, 2012, 26(10): 568-581. DOI: 10.1089/apc.2012.0169.
[30]	HHS. Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents 2011[EB/OL]. [2024-01-07].https://health.gov/healthypeople/tools-action/browse-evidence-based-resources/guidelines-use-antiretroviral-agents-adults-and-adolescents-living-hiv.
[31]	CRATER JM, NIXON DF, FURLER O'BRIEN RL. HIV-1 replication and latency are balanced by mTOR-driven cell metabolism[J]. Front Cell Infect Microbiol, 2022, 12: 1068436. DOI: 10.3389/fcimb.2022.1068436.
[32]	VARCO-MERTH BD, BRANTLEY W, MARENCO A, et al. Rapamycin limits CD4⁺ T cell proliferation in simian immunodeficiency virus-infected rhesus macaques on antiretroviral therapy[J]. J Clin Invest, 2022, 132(10): e156063. DOI: 10.1172/JCI156063.
[33]	PLANAS D, PAGLIUZZA A, PONTE R, et al. LILAC pilot study: effects of metformin on mTOR activation and HIV reservoir persistence during antiretroviral therapy[J]. EBioMedicine, 2021, 65: 103270. DOI: 10.1016/j.ebiom.2021.103270.
[34]	HENRICH TJ, SCHREINER C, CAMERON C, et al. Everolimus, an mTORC1/2 inhibitor, in ART-suppressed individuals who received solid organ transplantation: a prospective study[J]. Am J Transplant, 2021, 21(5): 1765-1779. DOI: 10.1111/ajt.16244.
[35]	MALAT GE, RANGANNA KM, SIKALAS N, et al. High frequency of rejections in HIV-positive recipients of kidney transplantation: a single center prospective trial[J]. Transplantation, 2012, 94(10): 1020-1024. DOI: 10.1097/TP.0b013e31826c3947.
[36]	LOCKE JE, JAMES NT, MANNON RB, et al. Immunosuppression regimen and the risk of acute rejection in HIV-infected kidney transplant recipients[J]. Transplantation, 2014, 97(4): 446-450. DOI: 10.1097/01.TP.0000436905.54640.8c.
[37]	WERBEL WA, BAE S, YU S, et al. Early steroid withdrawal in HIV-infected kidney transplant recipients: utilization and outcomes[J]. Am J Transplant, 2021, 21(2): 717-726. DOI: 10.1111/ajt.16195.
[38]	SANTEUSANIO A, BHANSALI A, DE BOCCARDO G, et al. Conversion to belatacept maintenance immunosuppression in HIV-positive kidney transplant recipients[J]. Clin Transplant, 2020, 34(10): e14041. DOI: 10.1111/ctr.14041.
[39]	EL SAKHAWI K, MELICA G, SCEMLA A, et al. Belatacept-based immunosuppressive regimen in HIV-positive kidney transplant recipients[J]. Clin Kidney J, 2020, 14(8): 1908-1914. DOI: 10.1093/ckj/sfaa231.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (11) PDF downloads(1)

Management of immunosuppressive drugs in HIV-positive solid organ transplant recipients

doi: 10.3969/j.issn.1674-7445.2024009

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Management of immunosuppressive drugs in HIV-positive solid organ transplant recipients

doi: 10.3969/j.issn.1674-7445.2024009

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Export File

Citation

Format

Content